Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06523543
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-15
Brief Title:
Ultra-early Identification of Fetal Chromosomal Characteristics From Extravillous-trophoblast Cells
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Ultra-early Identification of Fetal Chromosomal Characteristics From Extravillous-trophoblast Cells
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CellF-Cervix
Brief Summary:
Demonstrate the efficacy of an ultra-early non-invasive prenatal diagnostic method adaptable to various genetic indications to detect fetal chromosomal abnormalities
Detailed Description:
During pregnancy biological screening for genetic diseases of the fetus cannot be implemented before the 11th week of amenorrhea whatever the technique used This delay is long and distressing particularly for people at high risk of transmission of genetic diseases The presence of extravillous trophoblast cells to the cervix of the pregnant woman from the 7th week accessible by a cervicovaginal smear non-invasive represents new biological material representative of the fetal genome This project aimed at evaluating the performance of a method for analyzing these trophoblast cells extra-villous at the start of pregnancy The investigators want to evaluate performance analytical aspects of this method that is to say verifying that the genetic information resulting from these cells correspond to those of the fetus
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None